The effect of gonadotrophin releasing hormone analogue on height prognosis in growth hormone deficiency and normal puberty.
We have treated seven pubertal children, five (three female, two male) with growth hormone deficiency and two (one female, one male) with constitutional short stature with intranasal (D-Serine6) gonadotrophin releasing hormone (GnRH) analogue (Buserelin) for a mean of 0.84 years (range, 0.5-1.3). Treatment was successful in arresting pubertal development but there was no improvement in final height prognosis.
Stanhope
R
R
Department of Growth and Development, Institute of Child Health, London, United Kingdom.
Brook
C G
CG
D000281:Administration, Intranasal; D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006128:Growth / Q000187:drug effects; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D013006:Growth Hormone / Q000172:deficiency*; D006801:Humans; D008297:Male; D011379:Prognosis; D011627:Puberty / Q000187:drug effects*; D012741:Sexual Maturation / Q000187:drug effects
D013006:Growth Hormone; D002064:Buserelin